Last reviewed · How we verify
BI 3814916
At a glance
| Generic name | BI 3814916 |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BI 3814916 CI brief — competitive landscape report
- BI 3814916 updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI